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GLUCOCORTICOIDS are potent inhibitors of inflammation
and endotoxic shock. This probably occurs through an
inhibition of the synthesis of pro-inflammatory cytokines
as well as of many of their toxic activities. Therefore,
endogenous glucocorticoids (GC) might represent a major
mechanism in the control of cytokine mediated patholo-
gies. GC inhibit the synthesis of cytokines in various
experimental models. Adrenalectomy or GC antagonists
potentiate TNF, IL-1 and IL-6 production in LPS treated
mice. GC inhibit the formation of arachidonic acid
metabolites and the induction ofNO synthase. They also
inhibit various activities of cytokines including toxicity,
haemodynamic shock and fever. Adrenalectomy sensitizes
to the toxic effects of LPS, TNF and IL-1. On the other
hand, GC potentiate the synthesis of several cytokine
induced APP by the liver. Since many of these proteins
have anti-toxic activities (antioxidant, antiprotease etc.) or
bind cytokines, this might well represent a GC mediated
protective feedback mechanism involving the liver. Not
only do GC inhibit cytokines, but in vivo LPS and various
cytokines (TNF, IL-1, IL-6) increase blood GC levels
through a central mechanism involving the activation of
the HPA. Thus, this neuroendocrine response to cytokines
constitutes an important immunoregulatory feedback
involving the brain.
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Introduction
Glucocorticoids (GC) are effective in the
treatment of a variety of inflammatory and
autoimmune diseases and in these fields much of
current attention is focused on cytokines. This
review discusses the effects ofGC on the production
and actions of cytokines in order to obtain a better
understanding of how the anticytokine action of
GC is involved in their pharmacological activity.
This review focuses on the cytokines primarily
involved in the regulation of inflammatory
processes, IL-1, IL-6, IL-8 and TNF.
Most studies of pharmacological modulation of
cytokines have used animal models of endo-
toxaemia. In fact, endotoxin (lipopolysaccharide,
LPS) is a potent and widely used inducer of
cytokine production in vivo and on cultured cells,
and its toxic effects are antagonized by inhibitors or
antagonists of IL-1 or TNF.
1-3
The role of GC in the control of cytokine
mediated effects of LPS has been demonstrated by
two different approaches: removal of endogenous
GC (by adrenalectomy or GC-receptor antagonists),
or administration ofexogenous GC. Adrenalectomy
increases sensitivity to the lethal action of LPS4’5
and identical results have been obtained with the
GC receptor antagonist mifepristone (RU38486). 6’7
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Treatment with GC markedly protects against LPS
toxicity.
8-1 Susceptibility to the lethal action of
LPSll and TNF
2 varies with the circadian rhythm;
however, the role of endogenous GC is far from
being established. Biochemically, GC inhibit the
LPS induced production of inflammatory medi-
ators, such as arachidonic acid metabolites and
nitric oxide (NO). It is therefore important to define
which of these actions are due to inhibition of
cytokine production and which might involve a
direct inhibition of the cytokines’ action.
Inhibition of cytokine production
Exogenous glucocorticoids: Most of the in vitro studies
focused on IL-1 and TNF, whose induction is
suppressed by various GC (Table 1). IFNy can
partly overcome GC suppression of TNF produc-
tion in vitro by mouse peritoneal macrophages,
z6 In
contrast, IL-4 enhances the inhibitory action of GC
on IL-1, TNF and prostaglandins (PG) Ez
production by human monocytes.
27 However, GC
had no inhibitory effects when phorbol myristate
acetate (PMA) was used as a stimulus for TNF, IL-1
or IL-8 production. 17’21’2s
The inhibitory effect of GC on IL-1 production
may proceed through the inhibition of IL-1 gene
transcription and a decrease in the stability of
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Table 1. Inhibition of proinflammatory cytokine production by
glucocorticoids in vitro
Cytokine Inducer References
L- LPS, S. aureus, L- 13-15
TN F LPS, anti-IgG 16, 17
IL-6 LPS, IL-1, TNF 18, 19
IL-8 LPS, IL-1, TNF, cAMP 19-21
IL-2 IL-1 22
GM-CSF IL-1, TNF 19, 23
G-CSF IL-1, TNF 23, 24
MCP-1 IL-1 25
IL-interleukin; TNF, tumour necrosis factor; GM-CSF, granulo-
cyte-macrophage colony-stimulating factor; G-CSF, granulo-
cyte colony-stimulating factor; MCP-1, monocyte chemotactic
protein- 1.
IL-1 mRNA.
29 The fact that GC did not inhibit
PMA induced IL-1 might be explained by
postulating that PMA has a stabilizing effect on
IL-1 mRNA.
28 The inhibitory effect of GC on
IL-lfl gene expression was reversed by inhibitors
of protein synthesis.
29 This has some analogy with
other anti-inflammatory activities of GC that
require the synthesis of lipocortins.
3
Cytokines often induce each other, in a cascade
fashion, and GC inhibit IL-1 and TNF induction
of various cytokines (Fig. 1). In mice or rats
treated with LPS or anti-CD3 antibodies GC
inhibited the production of circulating TNF,
IL-1, IL-6 and IFNy.31-34 TNF seems to be more
sensitive to GC inhibition in vivo than IL-1 or
IL_6.35,36
GC inhibit TNF and IL-6 induced by stimuli
other than LPS. Dexamethasone (DEX) inhibited
TNF induction in mice after partial hepatectomy,
37
and IL-1 in a rat model of zymosan induced
INFECTION
CYTOKINES
TOXICITY PROTECTION
FIG. 1. Dual role of cytokines in infection and inflammation. Stimulation
of neuroendocrine system, by increasing endogenous GC, inhibits
cytokine production and potentiates cytokine induced protective
responses. The protective mechanism involving stimulation of APP
synthesis by the liver is depicted.
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pleurisy.
38 It also lowered serum IL-6 levels in
39 adjuvant arthritis in rats.
In human volunteers giving an injection of
LPS, GC inhibited IL-6 and TNF production.4’41
DEX, administered to IL-2 treated cancer patients
42
or to patients undergoing cardiopulmonary by-
pass,
43 reduced the TNF production observed in
these conditions.
Ex vivo studies on cells from patients with
sarcoidosis,
44 Crohn’s disease45 or rheumatoid
arthritis
46 found decreased IL-1, IL-6 and IL-8
production after GC treatment.
Effects of adrenalectomy or glucocorticoid antagonists: The
studies mentioned above employed exogenous GC.
More direct evidence of the inhibitory effect of
endogenous GC comes from studies where animals
were adrenalectomized (ADX) or treated with GC
antagonists. Adrenalectomy sensitizes to the lethal
action of infections, LPS,4’5 turpentine
4v or
complete Freund’s adjuvant.
48 This was related to
increased production of TNF and IL-1.
49
GC might be important in switching off TNF
production and, in fact, in ADX mice injected with
LPS, TNF levels remained elevated up to 5 h,
whereas in sham-operated mice they returned to
zero by 3 h.5 This prolonged induction was not
associated with higher peak TNF levels. In another
study, however,
sl ADX mice had higher peak
(1.5h) TNF levels, but the kinetics of TNF
induction was similar to that of intact mice,
returning to zero within 4 h. Unpublished data from
our laboratory agree with the latter report.
Production of IL-1 was also increased ex vivo, in
peritoneal macrophages from ADX rats.
s2 The
authors’ group reported that intracerebroven-
tricular (i.c.v.) injection of IL-1 in rats induced high
circulating levels of IL-6, and this effect was
potentiated by adrenalectomy.
53 The data on ADX
animals were confirmed by using RU38486 which
is reported to increase LPS toxicity and induction
of TNF and IL-6. 6’7 RU38486 also increased
mortality in a mouse model of septic peritonitis.
54
Effects on cytokine receptors
Glucocorticoids increase the expression of IL-1
receptors in B-lymphocytes, fibroblasts, and some
cell lines55’56 but not in T-lymphocytes, large
granular lymphocytes or monocytes. While this
increase in IL-1 receptors might seem paradoxical,
in view of the anti-inflammatory action of GC, it
could result in a change in IL-1 distribution in vivo,
where IL-1 might be soaked up by some ceils rather
than others.
This was also suggested in the case of IL-6 whose
receptor is markedly decreased by GC in monocytes
but not in hepatocytes. However, GC appeared toGlucocorticoids as cytokine inhibitors
be essential for the induction of hepatocyte IL-6
receptors by IL-1 and IL-6 itself, and it was
suggested that monocytes are normally involved in
binding trace amounts of IL-6, thus preventing its
interaction with the hepatocyte,
s7
Information on TNF receptors is scant; DEX
reduced the number of 75 kDa TNF receptors on
U937 cells
s8 but did not affect the number of TNF
binding sites on mouse hepatocytes in DEX treated
mice.
59
Effects on cytokine actions
Cytokines have a variety of actions on different
cells, resulting in various pathological effects
associated with infective or inflammatory diseases.6
The effects of anti-inflammatory agents, including
GC and non-steroidal anti-inflammatory drugs, on
the activities of TNF and IL-1 have been amply
documented. Here the effect of GC on various
activities of cytokines, in vivo and in vitro is reviewed.
In general, GC inhibit the pro-inflammatory and
toxic effects of cytokines. These effects belong
mainly to IL-1 and TNF, whose role as mediators
of the mortality associated with Gram-negative
septicaemia has been demonstrated by the protec-
tive effect of specific IL-1 and TNF inhibitors. 2’3’6
On the other hand, GC have been reported to
potentiate the induction of acute phase proteins
(APe).
Effects on inflammation:
A rachidonate metabolism. Prostaglandins and other
arachidonic acid oxygenation products are major
mediators of inflammation. Their production is
stimulated by IL-1,
61 and this was suggested to be
an important mechanism in the inflammatory and
pyrogenic action of IL-1.
Through GC induced lipocortin, GC inhibit the
activity and synthesis of PLA2,
62 the enzyme that
provides free arachidonic acid for PG synthesis.
IL-1, TNF and IFN2 induce PG synthesis by
stimulating PLA2 activity, and GC could inhibit
this.63-6s This suggests that the inhibitory effect of
GC is at the level of PLA2, since arachidonic acid
induced PG production was not reduced.63
Furthermore, GC inhibit the de novo synthesis of
cyclooxygenase induced by IL-1, TNF or LPS.
66-68
PLA2 is not implicated only in the inflammatory
action of cytokines but also in the tumoricidal
activity of TNF. GC inhibit the cytotoxic activity
of TNF on tumour cells in vitro69’7 as well as its
tumoricidal activity in vivo7 and it was suggested
this was due to inhibition of PLA2. Interestingly,
this activity of GC seems not to be mediated by
lipocortin,
v2
Chemotaxis and adherence. Pretreatment with DEX
abolished the neutrophil migration induced by
injection of IL-8 or IL-1 in rats or micev3-vs thus
suggesting that GC may directly inhibit IL-8
chemotactic activity, in addition to suppressing
IL-1 induced IL-8 production. The inhibitory effect
of GC on IL-1 induced chemotaxis seems to be
mediated by the induction of lipocortin which, in
fact, inhibits IL-1 induced chemot.axis, and
anti-lipocortin antibodies abolished the inhibitory
action of GC.
62 Contrasting indications were
obtained on the effect of GC on cytokine induced
expression of the adhesion molecule ICAM-1. 76’77
Nitric oxidepathway. Nitric oxide has been identified
as a major mediator of shock and inflammation. Its
production is increased by LPS, TNF, IL-1 and
IFN7 through the induction ofNO synthase.
78 GC
inhibited this induction by cytokines and LPS79’8
while not affecting its enzymatic activity.
8
Toxic, behavioural and catabolic effects: The most
impressive evidence for a protective role of
endogenous GC against the toxic effects of
cytokines comes from studies reporting that ADX
mice are sensitized to the lethal effects of IL-1 and
TNF;52’82 thus their increased sensitivity to LPS is
not only due to increased cytokine production (as
discussed above) but also to increased sensitivity to.
their actions. Similar results have been obtained
with RU38486.
3 Furthermore, DEX protected
against the lethal effect of a high dose of TNF in
intact mice without affecting its clearance, s9’71
The well-known haemodynamic effects of GC
might also be important in protecting against the
toxicity of IL-1 and TNF, which cause a marked
and often lethal hypotension.
84
GC might regulate other physiological responses
to infection too. For instance, ADX rats are more
susceptible to LPS induced fever
8s and GC
attenuated the sleep response to bacterial infection
in rabbits.
86 However, it is not clear whether the
effects of GC in these models are due to inhibition
of the production of cytokines or of their action.
Another well-known central effect of IL-1 and
TNF is anorexia. Contrasting results were reported;
one paper reported that DEX pre-treatment
blocked the suppression of food intake induced by
i.c.v. IL-1 administration in rats,
87 while another
showed that IL-1 induced anorexia was less
88 pronounced in ADX rats.
Effects on acute phase proteins: Induction of hepatic APP
is part of a reorientation of the liver metabolism
which includes an increase in the synthesis of APP
and a decrease in negative acute phase reactants. GC
are important for the induction of several APP, and
are required for the production of fibrinogen by
cultured hepatocytes stimulated with crude leuko-
cytic extract.
9 The permissive action of GC was
also reported in vivo where inflammatory stimuli
caused little or no induction of angiotensinogen,
9
haptoglobin
47 and 2-macrofetoprotein
9 in ADX
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animals. Among the various cytokines, those that
play a key role as hepatocyte stimulating factors
include IL-6, leukaemia inhibitory factor (LIF) and
oncostatin M (OM). Induction of most APP in
hepatoma cells stimulated in vitro with recombinant
preparations of these cytokines was potentiated by
GC.92-94
Induction ofAPP could be part of the protective
feedback response to infection and inflammation.
Some APP have activities that might be ’protecti-
ve’, either by binding cytokines, like 2-macro-
globulin;
95 by maintaining blood pressure, like
angiotensinogen;
9 or acting as antioxidants or
proteinase inhibitors. The protective role ofAPP is
elegantly demonstrated by Xia and Samols96 who
showed that transgenic mice overexpressing rabbit
C-reactive protein were protected against LPS or
IL-1/TNF induced lethality.
As mentioned above, some ’normal liver
proteins’ behave as negative acute phase reactants,
including albumin and cytochrome P-450. While
this can be explained on the basis of cell economy,
depression of cytochrome P-450 may have a
functional role. In fact, cytochromes of the P-450
family are also implicated in steroidogenesis and
TNF inhibited ACTH induced steroidogenic
cytochrome P-450, resulting in decreased GC
production.
97 This effect might limit the increase in
blood GC by TNF described below. It must also
be noted that cytochromes of the P-450 family are
implicated in the metabolism of arachidonic .acid,
thus suggesting another possible involvement in the
regulation of inflammation.
Effect of cytokines on
glucocorticoid receptors and action
Glucocorticoids are not only cytokine inhibitors
but, the other way round, cytokines may counteract
some effects of GC. As early as 1976, Moore et
a/.98’99 showed that GC induction of some enzymes
was inhibited by LPS; they identified a macrophage
product that was termed GAF (glucocorticoid
antagonizing factor). LPS also downregulates
hepatic GC receptors,
1 an effect that is tissue
specific since LPS had the opposite effect in
101 macrophages. Although the molecular structure
of GAF has never been identified it is conceivably
one of the several activities of IL-1, IL-6, TNF
or other known cytokines. In this respect, it is
interesting to note that IL-1 decreases hepatic GC
receptors thus inhibiting the induction of phos-
phoenolpyruvate carboxykinase.
12
Cytokine activation of the
hypothalamus-pituitary-adrenal axis
Inflammation and injection of LPS induce a rise.
in blood GC, due to activation ofthe hypothalamus-
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pituitary-adrenal axis (HPA).
a3 LPS induced GC
secretion in vivo is inhibited by selective depletion
of macrophages, suggesting that macrophage
derived cytokines mediate the effect of LPS.TM In
fact, treatment of mice with IL-1 increased blood
ACTH and GC levelsas and anti-IL-1 receptor
antibodies blocked LPS induced ACTH release.
16
While an earlier work reported that TNF had no
such effect, TNF and IL-6 also increased blood GC,
although they were less potent than IL-1.17’8
Although in different experimental models in
vitro, IL-1 and IL-6 directly stimulated the release
of ACTH from pituitary cells,19’11 the increase of
blood GC observed in vivo seems mainly due to a
stimulation of hypothalamic cells to release CRF.a
IL-1 induced GC was associated with increased
CRF levels in the pituitary portal vessels and
anti-CRF antibodies inhibited IL-1 induced GC,
thus indicating that IL-1 exerts this effect on the
hypothalamus.
112,113
A series of papers focused on the role of PG in
IL-1 activation of the HPA. The cyclooxygenase
inhibitor, indomethacin, inhibited CRF release in
vitroTM as well as activation of the HPA in vivo.s’16
Stress induced activation of the HPA is
downregulated by a feedback mechanism, and
inhibited by DEX pre-treatment. In comparison,
IL-1 induced HPA activation is less sensitive to the
inhibitory effect of DEX. As a possible explanation
for this difference, it was reported that IL-1
decreases hippocampal GC receptors thus desensi-
tizing them to DEX effects.7
HPA in the regulation of immunity, autoimmunity and
inflammation:
Immunity. Since GC are potent inhibitors of cytokine
production, cytokine activation of HPA might
obviously constitute a negative feedback mechan-
ism that regulates their production,
a5 To support
this theory, it was reported that hypophysectomized
animals produce more 1L-1, IL-6 and TNF.49’53
Activation of HPA by i.c.v, injected IL-1 resulted
in suppression of spleen macrophage IL-1 produc-
tion ex vivo, which was not observed in ADX
mice.
118
Another effect of central administration of IL-1
is to lower the peripheral cellular immune response
in terms of natural killer cell activity, lymphocyte
response to mitogens and IL-2 production.9’2
These effects were blunted by anti-CRF antibodies
and were less pronounced in ADX animals,
indicating that HPA is to some extent involved.
Autoimmune diseases. Experimental allergic en-
cephalomyelitis (EAE) is a demyelinating disease
induced by immunization to myelin basic protein,
and is used as an animal model for multiple
sclerosis. Recent data have indicated a pathogenetic
role of TNF in this disease, as demonstrated by theGlucocorticoids as cytokine inhibitors
protective effect of anti-TNF antibodies. 121 The role
of endogenous GC in the susceptibility to the
disease has been reviewed by Mason. 122 EAE
activates the HPA as revealed by the increase in
serum GC. ADX rats do not recover spontaneously
from EAE, and adrenalectomy increases the
mortality rate in this animal model. Rat strains that
are genetically resistant to the development ofEAE
have more marked HPA activation to stressing
stimuli, and adrenalectomy can render them
normally susceptible to EAE. These data on the
HPA regulation ofEAE provide a rationale for the
use of GC in the therapy of multiple sclerosis.
Inflammation. Since GC are potent anti-inflammatory
agents, HPA activation may also function to limit
inflammatory processes. TNF and IL-1 were
reported to have anti-inflammatory action in
carrageenan or dextran induced hind paw oedema
in rats.
123 This was due to the IL-1 and TNF
induced rise in GC, and was not observed in ADX
rats.
Lewis rats, which are genetically prone to
streptococcal cell wall (SCW) induced arthritis, had
markedly impaired ACTH and GC responses to
SCW or IL-1.124 On the other hand, RU38486
induced susceptibility to SCW arthritis in normal
rats. Thus genetic susceptibility to arthritis might
be related to a defective HPA responsiveness to
cytokines.
Glucocorticoid therapy in cytokine
mediated pathologies
In view of their potent anti-cytokine action, GC
might theoretically constitute drugs of choice in the
therapy of cytokine mediated pathologies, i.e. those
where a pathogenetic role of cytokines has been
demonstrated in animal models by the protective
action of anti-cytokine antibodies. The earliest
works of passive immunization of mice against
TNF showed that this cytokine is the key mediator
of mortality induced by LPS or Gram-negative
sepsis.2’3 As mentioned above, GC has a strong
protective effect in mice treated with lethal doses of
LPSs-l and septic shock was an indication for the
use of high GC doses.
12s
However, in clinical trials GC did not reduce
mortality in septic shock patients, and their
indication for use in this condition was withdrawn
by the FDA. 126’127 This discrepancy between animal
and clinical studies might have various reasons. For
instance, in most studies GC were administered to
animals before or concomitantly with LPS, a
situation that is quite different from a septic patient.
Furthermore, in septic shock patients, Gram-
negative sepsis is often associated with Gram-
positive infection,
128 and in mice where poly-
microbial sepsis was induced by caecal ligation and
puncture, anti-TNF antibodies and GC tended to
increase mortality. 129’13 These data indicate the
existence of a complex pathway where one must
consider the balance between the pathogenetic,
toxic activities of cytokines and their protective
actions against infection.TM
A different picture emerges on the role of TNF
and IL-1 in the pathogenesis of meningitis,132’133
where animal studies have shown a protective effect
of GC. In meningitis patients, antibiotic therapy
would result in bacterial cell lysis and consequent
liberation of LPS which would trigger the cytokine
cascade.TM It is therefore a current therapeutic
approach, supported by clinical trials, to administer
DEX 30 min before antibiotics to inhibit cytokine
production, thus preventing an important compo-
nent of the pathology.
Thus, glucocorticoids inhibit cytokines at
multiple sites. However, in most animal models
they are effective when given as pre-treatments, they
aspecifically inhibit the synthesis of all cytokines,
and they are also potent immunosuppressive agents.
This limits their effectiveness in the therapy of
cytokine mediated pathologies where a balance of
toxic versus protective effects of cytokines is likely
to exist.
References
1. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77:
1627-1652.
2. Beutler B, Milsark IW, Cerami AC. Passive immunization against
cachectin/turnour necrosis factor protects mice from lethal effect of
endotoxin. Science 1985; 229: 869-871.
3. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal
antibodies prevent septic shock during lethal bacteraemia. Nature 1987;
330: 662-664.
4. Abernathy RS, Halberg F, Spink WW. Studies the mechanism of
chlorpromazine protection against Brucella endotoxin in mice. J Lab Clin
Med 1957; 49: 708-715.
5. Swingle WW, Remington JW. Role of adrenal cortex in physiological
processes. Physiol Rev 1944; 24: 89-127.
6. Lazar G, Agarwal MK. The influence of novel glucocorticoid antagonist
endotoxin lethality in mice strains. Biochem Med Metab Biol 1986; 36:
70-74.
7. Hawes AS, Rock CS, Keogh CV, Lowry SF, Calvano SE. In vivo effects of
the antiglucocorticoid RU 486 glucocorticoid and cytokine responses to
Escberichia coli endotoxin. Infect Immun 1992; 60: 2641-2647.
8. Berry LJ, Smythe DS. Effects of bacterial endotoxins metabolism. VII.
Enzyme induction and cortisone protection. J Exp Med 1964; 120: 721-732.
9. Gadina M, Bertini R, Mengozzi M, Zandalasini M, Mantovani A, Ghezzi
P. Protective effect of chlorpromazine on endotoxin toxicity and TNF
production in glucocorticoid-sensitive and glucocorticoid-resistant models
of endotoxic shock. J Exp Med 1991 173: 1305-1310.
10. Evans GE, Zuckerman SH. Glucocorticoid-dependent and -independent
mechanisms involved in lipopolysaccharide tolerance. Eur J Immuno11991
21 1973-1979.
11. Halberg F, Johnson EA, Brown BW, Bittner JJ. Susceptibility rhythm to
E. coli endotoxin and bioassay. Proc Soc Exp Biol 1960; 103: 142-147.
12. Langevin T, Young J, Walker K, Roemeling R, Nygaard S, Hrunhesky
WJM. The toxicity of tumour necrosis factor (TNF) is reproducibly
different at specific times ofthe day. ProcA A Cancer Res 1987; 28: 398.
13. Arend WP, Massoni RJ. Characteristics of bacterial lipopolysaccharide
induction of interleukin-1 synthesis and secretion by human monocytes.
C/in Exp Immunol 1986; 64: 656-664.
14. Knudsen PJ, Dinarello CA, Strom TB. Glucocorticoids inhibit
transcriptional and post-transcriptional expression of interleukin-1 in U937
cells. J Immunol 1987; 139:4129-4134.
15. Ghezzi P, Dinarello CA. Interleukin-1 induces interleukin-1. III. Specific
inhibition of IL-1 production by IFN-y. J Immuno11988; 140: 4238-4244.
Mediators of Inflammation. Vol 2.1993 267G. Fantuzzi and P. Ghezzi
16. Beutler B, Krochin N, Milsark IW, Luedke C, Cerami A. Control of
cachectin (tumour necrosis factor) synthesis: mechanisms of endotoxin
resistance. Science 1986; 232: 977-980.
17. Debets JMH, Ruers TJM, Van der Linden MPMH, Van der Linden CJ,
Buurman WA. Inhibitory effect of corticosteroids the secretion of
tumour necrosis factor (TNF) by monocytes is dependent the stimulus
inducing TNF synthesis. Clin Exp Immunol 1989; 78: 224-229.
18. Waage A, Slupphaug G, Shalaby R. Glucocorticoids inhibit the production
of IL6 from monocytes, endothelial cells and fibroblasts. Eur J Immunol
1990; 20: 2439-2443.
19. Tobler A, Meier R, Seitz M, Dewald B, Baggiolini M, Fey MF.
Glucocorticoids downregulate gene expression of GM-CSF, NAP-1/IL-8
and IL-6, but not of M-CSF in human fibroblasts. Blood 1992; 79: 45-51.
20. Brown Z, Stricter RM, Chensue SW, et al. Cytokine-activated human
mesangial cells generate the neutrophil chemoattractant, interleukin 8.
Kidney Int 1991; 40: 86-90.
21. Anttila HSI, Reitamo S, Ceska M, Hurme M. Signal transduction pathways
leading to the production of IL-8 by human monocytes differentially
regulated by dexamethasone. Clin Exp Immunol 1992; 89: 509-512.
22. Tracey DE, Hardee MM, Richard KA, Paslay JW. Pharmacological
inhibition of interleukin-1 activity T-cells by hydrocortisone,
cyclosporine, prostaglandins and cyclic nucleotides. Immunopharmacology
1988; 15: 47-62.
23. Hamilton JA, Piccoli DS, Cebon J, et al. Cytokine regulation of
colony-stimulating factor (CSF) production in cultured human synovial
fibroblasts. II. Similarities and difference in the control of interleukin-1
induction of granulocyte-macrophage CSF and granulocyte-CSF produc-
tion. Blood 1992; 79: 1413-1419.
24. Kerner B, Teichmann B, Welte K. Dexamethasone inhibits tumour necrosis
factor-induced granulocyte colony-stimulating factor production in human
endothelial cells. Exp Hematol 1992; 20: 334-338.
25. Villiger PM, Terkeltaub R, Lotz M. Monocyte chemoattractant protein-1
(MCP-1) expression in human articular cartilage. Induction by peptide
regulatory factors and differential effects ofdexamethasone and retinoic acid.
J Clin Invest 1992; 90: 488-496.
26. Luedke CE, Cerami A. Interferon-y glucocorticoid suppression
of cachectin/tumour necrosis factor biosynthesis by murine macrophages.
J Clin Invest 1990; 86: 1234-1240.
27. Hart PH, Whitty GA, Burgess DR, Croatto M, Hamilton JA.
Augmentation of glucocorticoid action human monocytes by
interleukin-4. Lympbokine Res 1990; 9: 147-153.
28. Hurme M, Siljander P, Anttila H. Regulation of interleukin-lfl production
by glucocorticoids in human monocytes: the mechanism of action depends
the activation signal. Biochem Biophys Res Commun 1991; 180: 1383-1389.
29. Lee SW, Tsou A-P, Chan H, et al. Glucocorticoids selectively inhibit the
transcription of the interleukin 13 gene and decrease the stability of
interleukin 1/ mRNA. Proc NaNA cad Sci USA 1988; 85: 1204-1208.
30. Hiralta F, Schiffman D, Venkatasubramanian K, Salomon D, Axelrod J. A
phospholipase A inhibitory protein in rabbit neutrophils induced by
glucocorticoids. Proc Natl Acad Sci USA 1980; 77: 2533-2536.
31. Ulich TR, Guo K, Irwin B, Remick DG, Davatelis GN. Endotoxin-induced
cytokine gene expression in vivo. 1I. Regulation of tumour necrosis factor
and interleukin-l// expression and suppression. Am J Pathol 1990; 137:
1173-1185.
32. StaruchMj, Wood DD. Reduction of serum interleukin-l-like activity after
treatment with dexamethasone. J Leuk Biol 1985; 37: 193-207.
33. Waage A. Production and clearance of turnout necrosis factor in rats
exposed to endotoxin and dexamethasone. Clin Immunol Immunopatho11987;
45: 348-355.
34. Ferran C, Dy M, Merite S, et aL Reduction of morbidity and cytokine release
in anti-CD3 MoAb-treated mice by corticosteroids. Transplantation 1990;
50: 642-648.
35. Zuckerman SH, Evans GF, Butler LD. Endotoxin tolerance: independent
regulation of interleukin-1 and turnout necrosis factor expression. Infect
Immun 1991; 59: 2774-2780.
36. Sironi M, Gadina M, Kankova M, et al. Differential sensitivity of in vivo
TNF and IL-6 production to modulation by antiinflammatory drugs in mice.
Int J Immunopharmaco11992; 14: 1045-1050.
37. Satoh M, Adachi I<2, Suda T, Yamazaki M, Mizuno D. TNF-driven
inflammation during liver regeneration after partial hepatectomy and
its role in growth regulation of liver. Mol Biother 1991; 3: 136-147.
38. Perretti M, Solito E, Parente L. Evidence that endogenous interleukin-1 is
involved in leukocyte migration in acute experimental inflammation in rats
and mice. Agentse Actions 1992; 35: 71-78.
39. Theisen-Popp P, Pape H, Muller-Peddinghaus R. Interleukin-6 (IL-6) in
adjuvant arthritis of rats and its pharmacological modulation. Int J
Immunopbarmacol 1992; 14: 565-571.
40. Rock CS, Coyle SM, Keogh CV, et al. Influence of hypercortisolemia
the acute-phase protein response to endotoxin in humans. Surgery 1992; 112:
467-474.
41. Barber AE, Coyle SM, Marano MA, et al. Glucocorticoid therapy alters
hormonal and cytokine responses to endotoxin in J Immunol 1993;
150: 1999-2006.
42. Mier JW, Vachino G, Klempner MS, et al. Inhibition of interleukin-
2-induced tumour necrosis factor release by dexamethasone: prevention of
acquired neutrophil chemotaxis defect and differential suppression of
interleukin-2-associated side effects. Blood 1990; 76: 1933-1940.
43. Jansen NJ, Oeveren W, der Brock L, et al. Inhibition by
dexamethasone of the reperfusion phenomena in cardiopulmonary bypass.
J Thorac Cardiovasc Pulmonary Surg 1991" 102: 515-525.
44. Zabel P, Horst HJ, Kreiler C, Schlaak M. Circadian rhythm of interleukin-1
production of monocytes and the influence of endogenous and exogenous
glucocorticoids in Klin Wochenschr 1990; 68: 1217-1221.
45. Andus T, Gross V, Casar I, et al. Activation of monocytes during
inflammatory bowel disease. Pathobiolog 1991; 59: 166-170.
46. Seitz M, Dewald B, Gerber N, Baggiolini M. Enhanced production of
neutrcp-hii-activating peptide-1/interleukin-8 in rheumatoid arthritis. J Clin
Invest 1991;87: 463-469.
47. Krauss S. Response of haptoglobin to inflammation in
adrenalectomized rat. Proc Soc Exp Biol Med 1962; 112: 552-554.
48. Perretti M, Mugridge KG, Becherucci C, Parente L. Evidence that
interleukin-1 and lipoxygenase metabolites mediate the lethal effect of
complete Freund’s adjuvant in adrenalectomized rats. Lymphokine Cytokine
Res 1991" 10: 239-243.
49. Butler LD, Layman NK, Riedl PE, et al. Neuroendocrine regulation of in
vivo cytokine production and effects: I. In vivo regulatory networks involving
the neuroendocrine system, interleukin-1 and TNF-. J Neuroimmuno11989;
24: 143-153.
50. Zuckerman SH, Shellaas J, Butler LD. Differential regulation of
lipopolysaccharide-induced interleukin-1 and turnout necrosis factor
synthesis: effects ofendogenous and exogenous glucocorticoids and the role
of the pituitary-adrenal axis. Eur J Immuno11989; 19: 301-305.
51. Parant M, Le Contel C, Parant F, Chedid L. Influence of endogenous
glucocorticoid endotoxin-induced production of circulating TNF-.
Lymphokine Cytokine Res 1991; 10: 265-271.
52. Perretti M, Becherucci C, Scapigliati G, Parente L. The effect of
adrenalectomy interleukin-1 release in vitro and in vivo. Br J Pharmacol
1989; 98: 1137-1142.
53. De Simoni MG, Sironi M, De Luigi A, Manfridi A, Mantovani A, Ghezzi
P. Intracerebroventricular injection of interleukin-1 induces high circulating
levels of interleukin 6. J Exp Med 1990; 171: 1773-1778.
54. Lazar GJ, Lazar G, Agarwal MK. Modification of septic shock in mice by
the antiglucocorticoid RU 38486. Circ Shock 1992; 36: 180-184.
55. Akahoshi T, Oppenheim J, Matsushima K. Induction of high-affinity
interleukin-1 receptor human peripheral blood lymphocytes by
glucocorticoid hormones. J Exp Med 1988- 167: 924-936.
56. Gottschall PE, Koves K, Mizuno K, Tatsuno I, Arimura A. Glucocorticoid
upregulation interleukin-1 receptor expression in glioblastoma cell line.
Am J Physiol 1991" 261: E362-E368.
57. Bauer J, Lengyel G, Bauer TM, Acs G, Gerok W. Regulation of
interleukin-6 receptor expression in human monocytes and hepatocytes.
FEBS Lett 1989; 249: 27-30.
58. Chambaut-Guerin AM, Thomopoulos P. Regulation by dexamethasone and
1,25-dihydroxyvitamin D3 of the 75 Kd-type A tumour necrosis factor
receptor surface expression and mRNA level in human U937 ceils. Eur
Cytokine Netw 1991; 2: 355-360.
59. Libert C, Van Bladel S, Brouckaert P, Fiefs W. The influence of modulating
substances turnout necrosis factor and interleukin-6 levels after injection
of routine tumour necrosis factor lipopolysaccharide in mice. J Immunother
1991" 10: 227-235.
60. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. _N EnglJ Med
1993; 328: 106-113.
61. Dayer J-M, de Rochemonteix B, Burrus B, Demczuk S, Dinarello CA.
Human recombinant interleukin-1 stimulates collagenase and prostaglandin
E production by human synovial cells. J Clin Invest 1986; 77" 645-648.
62. Flower RJ. Lipocortin and the mechanism of action of the gluCocorticoids.
Br j Pharmacol 1988" 94: 987-1015.
63. Solito E, Parente L. Modulation of phospholipase A activity in human
fibroblasts. Br J Pbarmacol 1989; 96: 656-660.
64. Goppelt-Struebe M, Rehfeldt W. Glucocorticoids inhibit TNF-=-induced
cytosolic phospholipase A2 activity. Biocbim Biophys Acta 1992; 1127:
163-167.
65. Kawada N, Mizoguchi Y, Shin T, et al. Interferon gamma stimulates
prostaglandin Ez production by Kuppfer cells. Prostaglandins Leukot
Essent Fatty Acids 1990; 40: 275-279.
66. Raz A, Wyche A, Siegel N, Needleman P. Regulation of fibroblast
cyclooxygenase synthesis by interleukin-1. J Biol Chem 1988; 263:
3022-3028.
67. Masferrer JL, Zweifel BS, Seibert K, Needleman P. Selective regulation of
cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin
Invest 1990; 86: 1375-1379.
68. Coyne DW, Nickols M, Bertrand W, Morrison AR. Regulation of mesangial
cell cyclooxygenase synthesis by cytokines and glucocorticoids.A J Physiol
1992; 263: F97-F102.
69. Suffys P, Beyaert R, Van Roy F, Fiers W. Reduced tumour necrosis
factor-induced cytotoxicity by inhibitors ofthe arachidonic acid metabolism.
Biocbem Biophys Res Commun 1987; 149: 735-743.
70. Hepburn A, Boeynaems JM, Fiefs W, Dumont JE. Modulation of TNF-0
cytotoxicity in L929 cells by bacterial toxins, hydrocortisone and inhibitors
of arachidonic acid metabolism. Biocbem Biopbys Res Commun 1987; 149:
815-822.
71. Satomi N, Sakurai A, Haranaka R, Haranaka K. Preventive effects of several
chemicals against lethality of recombinant human tumour necrosis factor.
J Biol Response Mod 1988; 7: 54-64.
268 Mediators of Inflammation-Vol 2.1993Glucocorticoids as cytokine inhibitors
72. Beyaert R, Suffys P, Van Roy F, Fiers W. Inhibition by glucocorticoids of
turnout necrosis factor-mediated cytotoxicity. Evidence against lipocortin
involvement. FEBS Lett 1990; 262: 93-96.
73. Ribeiro RA, Flores CA, Cunha FQ, Ferreira SH. IL-8 in vivo
neutrophil migration by cell-dependent mechanism. Immunology 1991; 73:
472-477.
74. Perretti M, Flower RJ. Modulation of IL-l-induced neutrophil migration
by dexamethasone and lipocortin 1. J Immuno11993; 150: 992-999.
75. Maloff BL, Shaw JE, Di Meo TM. IL-1 dependent model of inflammation
mediated by neutrophils. J Pharmacol Meth 1989; 22: 133-140.
76. Colic M, Drabek D. Expression and function of intercellular adhesion
molecule (ICAM-1) rat thymic macrophages in culture. Immunol Lett
1991; 28: 251-257.
77. Detma M, Tenorio S, Hettmannsperger U, Ruszcak Z, Orfanos CE.
Cytokine regulation of proliferation and 1CAM-1 expression of human
dermal microvascular endothelial cells in vitro. J Invest Dermatol 1992; 98:
147-153.
78. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology,
pathophysiology, and pharmacology. Pharmacol Rev 1991 43: 109-141.
79. Pfeilschifter J, Schwarzenbach H. Interleukin-1 and tumour necrosis factor
stimulate cGMP formation in rat renal mesangial cells. FEBS Lett 1990;
273: 185-187.
80. Radomski MW, Palmer RM, Moncada S. Glucocorticoids inhibit the
expression of inducible, but not the constitutive, nitric oxide synthase
in vascular endothelial cells. Proc Natl A cad Sci USA 1990; 87:
10043-10047.
81. McCall TB, Palmer RM, Moncada S. Induction of nitric oxide synthase in
rat peritoneal neutrophils and its inhibition by dexamethasone. Eur J
Immuno11991 21: 2523-2527.
82. Bertini R, Bianchi M, Ghezzi P. Adrenalectomy sensitizes mice to the lethal
effects of interleukin-1 and tumour necrosis factor. J Exp Med 1988; 167:
1708-1712.
83. Brouckaert P, Everaerdt B, Fiefs W. The glucocorticoid antagonist
RU38486 mimics interleukin-1 in its sensitization to the lethal and
interleukin-6-inducing properties of tumour necrosis factor. Eur J Immunol
1992; 22: 981-986.
84. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA.
Interleukin-1 induces shockqike state in rabbits. Synergism with tumour
necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988;
81: 1162-1172.
85. Coelho MM, Souza GE, Pela IR. Endotoxin-induced fever is modulated
by endogenous glucocorticoids in rats.A J Physio11992; 263: R423-R427.
86. Toth LA, Gardiner TW, Krueger JM. Modulation of sleep by cortisone in
normal and bacterially infected rabbits. Am J Physiol 1992; 263:
R1339-R1346.
87. Plata-Salaman CR. Dexamethasone inhibits food intake suppression induced
by low doses of interleukin-lfl administered intracerebroventricularly. Brain
Res Bull 1991; 27: 737-738.
88. Pedersen P, Hasselgren PO, Li SJ, Hiyama DT, Fischer JE. Synthesis of
acute-phase proteins in perfused liver following administration of
recombinant interleukin-10 to normal adrenalectomized rats. J Surg Res
1988; 45: 333-341.
89. Rupp RG, Fuller GM. The effects of leucocytic and factors
fibrinogen biosynthesis in cultured hepatocytes. Exp Cell Res 1979; 118:
23-30.
90. Okamoto H, Ohashi Y, Itoh N. Involvement of leukocyte and
glucocorticoid in the acute-phase response of angiotensinogen. Biochem
Biophys Res Commun 1987; 145: 1225-1230.
91. Sobocinski PZ, Canterbury w j, Knutsen GL, Hauer EC. Effect of
adrenalectomy cadmium- and turpentine-induced hepatic synthesis of
metallothionein and 02-macrofetoprotein in the rat. Inflammation 1981; 5:
153-164.
92. Castell JV, Gomez-LechonMJ, David M, Hirano T, Kishimoto T, Heinrich
PC. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the
synthesis of acute phase proteins in human hepatocytes. FEBS Lett 1988;
232: 347-350.
93. Baumann H, Wong GG. Hepatocyte-stimulating factor III shares structural
and functional identity with leukemia-inhibitory factor. J Immunol 1989;
143 1163-1167.
94. Richards CD, Brown TJ, Shoyab M, Baumann H, Gauldie J. Recombinant
oncostatin M stimulates the production of acute phase proteins in
hepG2 cells and rat primary hepatocytes in vitro. J Immunol 1992; 148:
1731-1736.
95. Borth W, Luger TA, Identification of 02-macroglobulin cytokine plasma
protein. J Biol Chem 1989; 264: 5818-5825.
96. Xia D, Samols D. Protective effects of rabbit C-reactive protein (RAB-CRP)
against mediators of septic shock. FASEB J 1992; 6: A1344.
97. Jaattela M, Ilvesmaki V, Voutilainen R, Stenman UH, Saksela E. Tumour
necrosis factor potent inhibitor of adrenocorticotropin-induced cortisol
production and steroidogenic P450 enzyme gene expression in cultured
human fetal adrenal cells. Endocrinology 1991; 128: 623-629.
98. Moore RN, Goodrum KJ, Berry LJ. Mediation of endotoxic effect by
macrophages. J Reticuloendothel Soc 1976; 19: 187-197.
99. Moore RN, Goddrum KJ, Couch REJ, Berry LJ. Elicitation of
endotoxemic effects in C3H/HeJ mice with glucocorticoid antagonizing
factor and partial characterization of the factor. Infect Immun 1978; 19:
79-86.
100. Stith RD, McCallum RE. Down regulation of hepatic glucocorticoid
receptors after endotoxin treatment. Infect Immun 1983; 40: 613-621.
101. Salkowski CA, Vogel SN. Lipopolysaccharide increases glucocorticoid
receptor expression in murine macrophages. J Immunol 1992; 149:
4041-4047.
102. Hill MR, Stith RD, McCallum RE. Interleukin-l: regulatory role in
glucocorticoid-regulated hepatic metabolism. JImmuno11986; 137: 858-862.
103. Besedovsky HO, Sorkin E, Keller M, Muller J. Changes in blood hormone
levels during the immune response. Proc Soc Exp Biol Med 1975; 150:
466-470.
104. Derijk R, Van Rooijen N, Tilders FJ, Besedovsky HO, Del Rey A,
Berkenbosh F. Selective depletion of macrophages prevents pituitar-
y-adrenal activation in response to subpyrogenic, but not pyrogenic, doses
of bacterial endotoxin in rats. Endocrinology 1991; 129: 330-338.
105. Besedowsky H, del Rey A, Sorkin E, Dinarello CA. Immunoregulatory
feedback between interleukin-1 and glucocorticoid hormones. Science 1986;
233: 652-654.
106. Rivier C, Chizzonite R, Vale W. In the mouse, the activation of the
hypothalamic-pituitary-adrenal axis by lipopolysaccharide (endotoxin) is
mediated through interleukin-1. Endocrinology 1989; 125: 2800-2805.
107. Mefford IN, Masters CF, Heyes MP, Eskay RL. Cytokine-induced activation
of the neuroendocrine stress axis persists in endotoxin-tolerant mice. Brain
Res 1991; 557: 327-330.
108. Perlstein RS, Mougey EH, Jackson WE, Neta R. Interleukin-1 and
interleukin-6 act synergistically to stimulate the release of adrenocortico-
tropic hormone in vivo. Lymphokine Cytokine Res 1991; 10: 141-146.
109. Woloski BMRNJ, Smith EM, Meyer WJI, Fuller GM, Blalock JE.
Corticotropin-releasing activity of monokines. Science 1985;230:1035-1037.
110. Bernton EW, Beach JE, Holaday JW, Smallridge RC, Fein HG. Release
of multiple hormones by direct action of interleukin-1 pituitary cells.
Science 1987; 238: 519-521.
111. Tsagarakis S, Gillies G, Rees LH, Besser M, Grossman A. Interleukin-1
directly stimulates the release of corticotropin releasing factor from rat
hypothalamus. Neuroendocrinology 1989; 49: 98-101.
112. Sapolsky R, Rivier C, Yamamoto G, Plotsky P, Vale W. Interleukin-1
stimulates the secretion of hypothalamic corticotropin-releasing factor.
Science 1987; 238: 522-524.
113. Berkenbosch F, Oers J, del Rey A, Tilders F, Besedovsky H.
Corticotropin-releasing factor-producing neurons in the rat activated by
interleukin-1. Science 1987; 238: 524-526.
114. Bernardini R, Calogero AE, Mauceri G, Chrousos GP. Rat hypothalamic
corticotropin-releasing hormone secretion in vitro is stimulated by
interleukin-1 in eicosanoid-dependent L/re Sci 1990; 47:
1601-1607.
115. Katsuura G, Gottschall PE, Dahl RR, Arimura A. Adrenocorticotropin
release induced by intracerebroventricular injection of recombinant human
interleukin-1 in rats: possible involvement of prostaglandin. Endocrinology
1988; 122: 1737-1779.
116. Morimoto A, Murakami N, Nakamori T, Sakata Y, Watanabe T. Possible
involvement of prostaglandin E in development ofACTH response in rats
induced by human recombinant interleukin-1. J Physio11989; 411: 245-256.
117. Weidenfeld J, Abramsky O, Ovadia H. Effect of interleukin-1 ACTH
and corticosterone secretion in dexamethasone and adrenalectomized
pretreated male rats. Neuroendocrinology 1989; 50: 650-654.
118. Brown R, Li Z, Vriend CY, et al. Suppression of splenic macrophage
interleukin-1 secretion following intacerebroventricular injection of
interleukin-lfl: evidence for pituitary-adrenal and sympathetic control. Cell
Immunol 1991; 132: 84-93.
119. Sundar SK, Becket KJ, Cierpial MA, et al. Intracerebroventricular infusion
of interleukin-1 rapidly decreases peripheral cellular immune responses. Proc
NatlAcadSd USA 1989; 86: 6398-6402.
120. Sundar SK, Cierpial MA, Kilts C, Ritchie JC, Weiss JM. Brain IL-l-induced
immunosuppression through activation of both pituitary-adrenal
axis and sympathetic system by corticotropin-releasing factor. J
Neurosci 1990; 10: 3701-3706.
121. Ruddle NH, Bergman CM, McGrath KM, et al. An antibody to
lymphotoxin and tumour necrosis factor prevents transfer of experimental
allergic encephalomyelitis. J Exp Med 1990; 172: 1193-1200.
122. Mason D. Genetic variation in the stress response: susceptibility to
experimental allergic encephalomyelitis and implications for human
inflammatory disease. Immunol Today 1991; 12: 57-60.
123. Nakamura H, Motoyoshi S, Kadokawa T. Anti-inflammatory action of
interleukin through the pituitary-adrenal axis in rats. Eur J Pharmacol
1988; 151 67-73.
124. Sternberg EM, Hill JM, Chrousos GP, et al. Inflammatory mediator-induced
hypothalamic-pituitary--adrenal axis activation is defective in streptococcal
cell wall arthritis-susceptible Lewis rats. Proc NatlA cad Sd USA 1989; 86:
2374-2378.
125. Sheagren JN. Septic shock and corticosteroids. N Engl J Med 1981; 305:
456-457.
126. Veterans Administration Systemic Sepsis Cooperative Study Group. Effect
of high-dose glucocorticoid therapy mortality in patients with clinical
signs of systemic sepsis. N Engl J Med 1987; 317: 659-665.
127. Bone RC, Fisher C J, Clemmer TP, et aL A controlled clinical trial of
high-dose methylprednisolone in the treatment of severe sepsis and septic
shock. N EnglJ Med 1987; 317: 653-658.
128. Munoz C, Cadet J, Fitting C, Misset B, Bl6riot J-P, Cavaillon J-M.
Mediators of Inflammation. Vol 2. 1993 269G. Fantuzzi and P. Ghezzi
Dysregulation of in vitro cytokine production by monocytes during sepsis.
J Clin Invest 1991; 88: 1747-1754.
129. Baker CC, Chaudry IH, Gaines HO, Baue AE. Evaluation of factors
affecting mortality rate after sepsis in murine cecal ligation and puncture
model. Surgery 1983; 94: 331-335.
130. Echtenacher B, Falk W, Mannel D, Krammer PH. Requirement of
endogenous tumour necrosis factor/cachectin for recovery from experi-
mental peritonitis. J Immuno11990; 145: 3762-3768.
131. der Meer JWM, Barza M, Wolff SM, Dinarello CA. A low dose of
recombinant interleukin-1 protects granulocytopenic mice from lethal
Gram-negative infection. Proc NatlA cad Sci USA 1988; 85: 1620-1623.
132. Ramilo O, Saez-Llorens X, Mertsola J, et al. Tumour necrosis factor
0/cachectin and interleukin-1/ initiate meningeal inflammation. J Exp Med
1990; 172: 497-507.
133. Saukkonen K, Sande S, Cioffe C, Wolpe S, Sherry B, Cerami A. The role
of cytokines in the generation of inflammation and tissue damage in
experimental Gram-positive meningitis. J Exp Med 1990; 171: 439-448.
134. Mustafa MM, Ramilo O, Saez-Llorens X, Olsen KD, Magness RR,
McCracken GHJ. Cerebrospinal fluid prostaglandins, interleukin-1/, and
tumour necrosis factor in bacterial meningitis. Clinical and laboratory
correlations in placebo-treated and dexamethasone-treated patients. Am J
Dis Child 1990; 144: 883.
ACKNOWLEDGEMENT. G.F. is recipient of fellowship from Consorzio
Domp&/Biolaq, L’Aquila, Italy.
Received 29 April 1993;
accepted 3 May 1993
270 Mediators of Inflammation. Vol 2.1993